Gadobutrol - Bayer HealthCare Pharmaceuticals
Alternative Names: BAY-864875; Gadavist; Gadobutrol injection for MRI of CNS - Bayer; Gadovist; Gadovist 1.0; Gd-DO3A-butriol; SHL 562Latest Information Update: 05 Nov 2023
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals
- Class Gadolinium-containing contrast agents; Organometallic compounds; Small molecules
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Coronary artery disease; Vascular disorders
- No development reported Brain cancer
Most Recent Events
- 29 Nov 2022 No development reported - Phase-III for Coronary artery disease (Diagnosis) in Australia (IV)
- 29 Nov 2022 No development reported - Phase-III for Coronary artery disease (Diagnosis) in Canada (IV)
- 29 Nov 2022 No development reported - Phase-III for Coronary artery disease (Diagnosis) in France (IV)